Showing 4,841 - 4,860 results of 7,608 for search '"oncology"', query time: 0.09s Refine Results
  1. 4841
  2. 4842
  3. 4843
  4. 4844
  5. 4845
  6. 4846
  7. 4847

    DIAGNOSTIC COMPETENCE IN BONE TUMORS: INFLUENCE OF ONCO-ORTHOPEDIC TRAINING by Julia Pozzetti Daou, Caio Falk Giannotti, Jairo Greco Garcia, Marcelo de Toledo Petrilli, Dan Carai Maia Viola, Reynaldo Jesus Garcia Filho

    Published 2025-02-01
    “…Methods: The sample consisted of 90 participants who answered the questionnaire: 18 orthopedic oncology specialists, 58 non-specialist orthopedists, and 14 orthopedic residents. …”
    Get full text
    Article
  8. 4848
  9. 4849
  10. 4850
  11. 4851
  12. 4852
  13. 4853

    First Indonesian Nasopharyngeal Cancer Whole Epigenome Sequencing Identify Tumour Suppressor CpG Methylation by Handoko, Adham M, Rachmadi L, Tobing DL, Asmarinah A, Fadilah F, Dai W, Lee AWM, Gondhowiardjo SA

    Published 2025-01-01
    “…Handoko,1– 3 Marlinda Adham,2,4 Lisnawati Rachmadi,2,5 Demak Lumban Tobing,6 Asmarinah,7 Fadilah,8 Wei Dai,9,10 Anne Wing Mui Lee,10 Soehartati A Gondhowiardjo2,3 1Doctoral Program in Biomedical Sciences, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; 2Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; 3Department of Radiation Oncology, Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia; 4Department of Otorhinolaryngology - Head and Neck Surgery, Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia; 5Department of Anatomical Pathology, Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia; 6Department of Clinical Pathology, Dharmais Cancer Hospital, Jakarta, Indonesia; 7Medical Biology Department, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia; 8Department of Medical Chemistry, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia-Bioinformatics Core Facilities, Indonesian Medical Education and Research Institute (IMERI), Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; 9Department of Clinical Oncology, University of Hong Kong, Pokfulam, Hong Kong (SAR), People’s Republic of China; 10Clinical Oncology Center, University of Hong Kong – Shenzhen Hospital, Shenzhen, People’s Republic of ChinaCorrespondence: Soehartati A Gondhowiardjo; Handoko, Email handoko12@ui.ac.idIntroduction: Nasopharyngeal cancer (NPC) is a multifaceted disease characterized by genetic and epigenetic modifications. …”
    Get full text
    Article
  14. 4854
  15. 4855
  16. 4856
  17. 4857
  18. 4858

    High tumor mutational burden predicts favorable response to anti-PD-(L)1 therapy in patients with solid tumor: a real-world pan-tumor analysis by Sehhoon Park, Jaeyun Jung, You Jeong Heo

    Published 2023-04-01
    “…Background Tumor mutation burden (TMB) is an important biomarker to predict response to anti-PD-L1 treatment across cancer types. TruSight Oncology 500 (TSO500) is currently used globally as a routine assay for TMB.Methods Between 2019 and 2021, 1744 patients with cancer received TSO500 assay as part of a real-world clinical practice at the Samsung Medical Center, and 426 received anti-PD-(L)1 treatment. …”
    Get full text
    Article
  19. 4859
  20. 4860